Two-Year Follow-Up Data On The Efficacy And Safety Of Kn026, A Her2-Targeted Bispecific Antibody Combined With Docetaxel As First-Line Treatment For Her2-Positive Recurrent /Metastatic Breast Cancer.
Docetaxel;KN-026
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Two-Year Follow-Up Data On The Efficacy And Safety Of Kn026, A Her2-Targeted Bispecific Antibody Combined With Docetaxel As First-Line Treatment For Her2-Positive Recurrent /Metastatic Breast Cancer. ### Output: Docetaxel;KN-026